Actively Recruiting
Phase III Study Comparing Intravesical SHR-1501 Plus BCG to Chemotherapy in Adults With BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2026-07-20
236
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of a combination treatment involving intravesical SHR-1501 and Bacillus Calmette Guerin BCG compared to investigator-selected chemotherapy in patients with BCG-unresponsive papillary-only non-muscle-invasive bladder cancer NMIBC. This phase III, multicenter, randomized, open-label study aims to provide new insights into treatment options for this condition. Participants will be randomly assigned to receive either the combination of SHR-1501 and BCG or one of several chemotherapy drugs chosen by the investigator, including Epirubicin, Pirarubicin, Gemcitabine, Hydroxycamptothecin, or Mitomycin. Treatments are administered via injections directly into the bladder. The study will follow participants for up to approximately 5 years to assess outcomes. During the study, participants will undergo regular assessments to monitor disease-free survival and overall survival. Safety will be evaluated by tracking adverse events and serious adverse events throughout the study duration. The primary outcome is disease-free survival, assessed centrally by blinded independent review. The total participation time may extend up to 5 years, during which multiple visits and evaluations will take place to ensure thorough monitoring of treatment effects and safety.
CONDITIONS
Brief Title
A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
Research Team
W
Wenliang Wang
Q
Qi Zhang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here